Logo image of CYCC

CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Price, Quote, News and Overview

NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock - Currency: USD

1.75  -0.25 (-12.5%)

After market: 1.85 +0.1 (+5.71%)

CYCC Quote, Performance and Key Statistics

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (5/20/2025, 8:00:01 PM)

After market: 1.85 +0.1 (+5.71%)

1.75

-0.25 (-12.5%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High49.34
52 Week Low1.67
Market Cap667.10M
Shares381.20M
Float186.46M
Yearly Dividend0.03
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO01-01 1996-01-01


CYCC short term performance overview.The bars show the price performance of CYCC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

CYCC long term performance overview.The bars show the price performance of CYCC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CYCC is 1.75 USD. In the past month the price decreased by -51.52%. In the past year, price decreased by -94.66%.

CYCLACEL PHARMACEUTICALS INC / CYCC Daily stock chart

CYCC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18 327.00B
AMGN AMGEN INC 13.25 147.86B
GILD GILEAD SCIENCES INC 14.1 135.84B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.96B
REGN REGENERON PHARMACEUTICALS 13.87 66.38B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.94B
ARGX ARGENX SE - ADR 98.52 35.31B
ONC BEIGENE LTD-ADR 5.89 25.53B
BNTX BIONTECH SE-ADR N/A 24.45B
NTRA NATERA INC N/A 21.01B
BIIB BIOGEN INC 8.25 19.13B
SMMT SUMMIT THERAPEUTICS INC N/A 18.11B

About CYCC

Company Profile

CYCC logo image Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.

Company Info

CYCLACEL PHARMACEUTICALS INC

200 Connell Dr Ste 1500

Berkeley Heights NEW JERSEY 07922 US

CEO: Spiro Rombotis

Employees: 12

CYCC Company Website

CYCC Investor Relations

Phone: 19085177330

CYCLACEL PHARMACEUTICALS INC / CYCC FAQ

What is the stock price of CYCLACEL PHARMACEUTICALS INC today?

The current stock price of CYCC is 1.75 USD. The price decreased by -12.5% in the last trading session.


What is the ticker symbol for CYCLACEL PHARMACEUTICALS INC stock?

The exchange symbol of CYCLACEL PHARMACEUTICALS INC is CYCC and it is listed on the Nasdaq exchange.


On which exchange is CYCC stock listed?

CYCC stock is listed on the Nasdaq exchange.


What is CYCLACEL PHARMACEUTICALS INC worth?

CYCLACEL PHARMACEUTICALS INC (CYCC) has a market capitalization of 667.10M USD. This makes CYCC a Small Cap stock.


How many employees does CYCLACEL PHARMACEUTICALS INC have?

CYCLACEL PHARMACEUTICALS INC (CYCC) currently has 12 employees.


Is CYCLACEL PHARMACEUTICALS INC (CYCC) expected to grow?

The Revenue of CYCLACEL PHARMACEUTICALS INC (CYCC) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the CYCC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CYCLACEL PHARMACEUTICALS INC (CYCC) stock pay dividends?

CYCC does not pay a dividend.


When does CYCLACEL PHARMACEUTICALS INC (CYCC) report earnings?

CYCLACEL PHARMACEUTICALS INC (CYCC) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of CYCLACEL PHARMACEUTICALS INC (CYCC)?

CYCLACEL PHARMACEUTICALS INC (CYCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.49).


What is the Short Interest ratio of CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

The outstanding short interest for CYCLACEL PHARMACEUTICALS INC (CYCC) is 1.45% of its float. Check the ownership tab for more information on the CYCC short interest.


CYCC Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CYCC Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CYCC. CYCC may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CYCC Financial Highlights

Over the last trailing twelve months CYCC reported a non-GAAP Earnings per Share(EPS) of -3.49. The EPS increased by 75.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -273.86%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%94.55%
Sales Q2Q%-100%
EPS 1Y (TTM)75.15%
Revenue 1Y (TTM)-89.69%

CYCC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to CYCC. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCC


Ownership
Inst Owners6.51%
Ins Owners0.91%
Short Float %1.45%
Short Ratio0.89
Analysts
Analysts43.33
Price TargetN/A
EPS Next Y39.49%
Revenue Next Year88.68%